Skip to content

Reported May 8, 2025 · Before market open

EPS-$0.74Beat by $0.04
EPS estimate-$0.78

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$3.7M
EPS estimate-$0.80

Financials

Q1 2025

Income statement

See full
Operating income-$55.0M-27.9%
Net income-$48.5M-30.6%

Balance sheet

See full
Cash & equivalents$76.7M+3.3%
Total debt$1.8M-41.9%
Total equity$551.8M+29.6%
Total assets$579.7M+29.0%

Cash flow

See full
Operating cash flow-$43.2M-12.8%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$442.94M-39.3%
Enterprise value$368.13M-44.1%

Returns & leverage

See full
Return on equity-36.6%+12.8pp
Debt / equity0.0×
Current ratio11.6×-8.7×

Versus estimates

Ask the moment Cullinan Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Cullinan Therapeutics, Inc. report Q1 2025 earnings?
Cullinan Therapeutics, Inc. (CGEM) reported Q1 2025 earnings on May 8, 2025 before market open.
What were Cullinan Therapeutics, Inc.'s Q1 2025 revenue and EPS?
Cullinan Therapeutics, Inc. reported eps of $-0.74 for Q1 2025.
Did Cullinan Therapeutics, Inc. beat estimates in Q1 2025?
EPS beat the consensus estimate of $-0.78 by $0.04.
How did Cullinan Therapeutics, Inc.'s Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 14.0% from $-0.86.
Where can I find Cullinan Therapeutics, Inc.'s Q1 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-066384) directly on SEC EDGAR. The filing index links above go to sec.gov.